CARDINAL HEALTH INC

Cardinal Health insider sales by COO Mary Scherer show routine portfolio rebalancing, not a warning—stable fundamentals, strong growth, and strategic expansion remain in focus.

Cardinal Health insider selling spree: CEO and execs liquidate ~150,000 shares, but strong earnings and routine vesting suggest no panic.

Cardinal Health insider buys 381 shares before earnings, signaling confidence in future growth and robust sales of newly approved oncology drugs, with ongoing safety and regulatory updates.

Cardinal Health insider sales surge in Q1 2026—what the modest $229.72 share deals mean for future growth and stock volatility.